Bellevue Life Sciences Acquisition Corp. (BLAC) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Bellevue Life Sciences Acquisition Corp. (BLAC:NASDAQ), powered by AI.

Current Price
$0.41
P/E Ratio
7.8
Market Cap
3M
Sector
Financial Services
What is the Bellevue Life Sciences Acquisition Corp. stock price forecast?

Bellevue Life Sciences Acquisition Corp. is currently trading at $0.41. View real-time AI analysis on Alpha Lenz.

What is Bellevue Life Sciences Acquisition Corp. insider trading activity?

View the latest insider trading data for Bellevue Life Sciences Acquisition Corp. on Alpha Lenz.

What is Bellevue Life Sciences Acquisition Corp.'s P/E ratio?

Bellevue Life Sciences Acquisition Corp.'s P/E ratio is 7.8.

Bellevue Life Sciences Acquisition Corp.

NASDAQ · BLAC
$0.41-0.02(-4.65%)Pre-marketNASDAQ regular session 09:30–16:00 ET
Ask about Bellevue Life Sciences Acquisition Corp.'s future dividend policy...
Alpha Chat Insight

Bellevue Life Sciences Acquisition Corp. trades at a P/E of 7.8 (undervalued) with modest ROE of 2.5%.

Ask for details

Company Overview

Bellevue Life Sciences Acquisition Corp. is a special purpose acquisition company (SPAC) focused on identifying and merging with a business in the life sciences sector. Designed to facilitate companies seeking public investment without undergoing a traditional Initial Public Offering (IPO), it raises capital through its own initial listing to fund potential acquisition targets. Bellevue Life Sciences Acquisition Corp. primarily targets industries such as biotechnology, pharmaceuticals, medical devices, and diagnostic services, which are pivotal for advancing healthcare solutions and technological innovations in medicine. The company leverages its leadership's expertise in navigating complex public markets and facilitating strategic growth for its chosen partner. As a SPAC, its significance in the financial market lies in its ability to provide a streamlined path for life sciences companies to access public capital, thereby accelerating research, development, and commercialization efforts in critical health-related fields. Through its structured approach, Bellevue Life Sciences Acquisition Corp. plays a vital role in expanding investment opportunities and fostering advancement in the high-demand area of life sciences.

CEOMr. Kuk Hyoun Hwang
SectorFinancial Services
IndustryShell Companies
0

Company Statistics

FY 2023

Profile

$3.15MMarket Cap
$0.00Revenue
0.00Shares Out
0Employees

Margins

N/AGross
N/AEBITDA
N/AOperating
N/APre-Tax
N/ANet

Valuation

7.81P/E
0.10P/B
N/AEV/Sales
-1.71EV/EBITDA
-3.85P/FCF

Growth (CAGR)

N/ARev 3Yr
N/ARev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

2.13%ROA
2.49%ROE
-9.67%ROIC

Financial Health

$15.42KCash & Cash Equivalents
$4.09MNet Debt
12.63%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Bellevue Life Sciences Acquisition Corp. (ticker: BLAC) is a company listed on NASDAQ in the Financial Services sector (Shell Companies). Market cap is $3M.

The current price is $0.41 with a P/E ratio of 7.81x and P/B of 0.1x.

ROE is 2.49%.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Bellevue Life Sciences Acquisition Corp. (BLAC) Stock Forecast 2026 $0.41 — Price, Financials & Analyst Targets | Alpha Lenz